Developer docs
API playgroundTry for free, no card

Search company profiles

1Cell.Ai

Full company profile

uuid0097nlv

Namestring
1Cell.Ai
Legal namestring
1Cell.Ai Inc.
Websiteurl
1cell.ai
Company typeenum
Private
Founded yearint
2019
Descriptiontext

1Cell.Ai is a precision oncology company that applies AI to single-cell multi-omic analysis for cancer diagnostics. Originally founded as OneCell Diagnostics in 2019 and rebranded in April 2025, the company operates a CLIA/CAP certified laboratory in Foster City, California and an NABL accredited laboratory in Pune, India, with a regional headquarters in Mumbai. Its core technology stack combines a proprietary live circulating tumor cell (CTC) capture platform (Cell Biopsy®, OncoIncytes®) achieving over 82% single-cell capture efficiency, an AI-driven automated single-cell isolation system (1Cell SOLO®), and an AI-powered informatics platform (1Cell iCore™ with iDiscover and iCare modules) that integrates genomic, transcriptomic, proteomic, imaging, and clinical data with real-world evidence. AI capabilities span deep-learning digital pathology (OncoPredikt, TRINITYAI), ctDNA methylation-driven MRD detection (MIRAGE), predictive therapy response modeling, and variant interpretation ML.

The company's product portfolio is organized into a global platform (OncoIncytes, 1Cell SOLO, 1Cell iCore) and an India-focused diagnostic suite (OncoIndx comprehensive 1,000+ gene NGS profiling, OncoIndx Prime+ matched tissue-liquid-normal NGS, OncoRisk hereditary 74-gene panel, OncoHRD for PARP inhibitor guidance, OncoMonitor longitudinal CTC/ctDNA monitoring, OncoTarget disease-specific panels, OncoIndx 360° Endometrium, and DrG/OSakhi clinician and patient companion platforms). All tests are supported by AI-powered interpretation through the iCare™ platform and validated under CAP/CLIA/NABL/ISO quality systems.

Revenue is generated through three streams: one-time diagnostic testing services sold quote-based to hospitals and oncologists, clinical research and biomarker discovery services for biopharma partners, and recurring biopharma partnerships for trial support and companion diagnostic development. GTM is enterprise field sales augmented by active presence at major oncology conferences (AACR, SABCS, ESMO, ISLB, World ADC). Strategic alliances include BioSkryb Genomics (single cell multi-omics co-development, April 2025), AccuGenomics (Accukit integration for Asia scale-up, October 2025), and Georgia Cancer Centre (CLIA-grade validation, May 2025). Customers served include 100+ hospitals, 1,000+ clinicians, and 50,000+ patients cumulatively, with primary segments being clinicians/oncologists and pharma/biopharma partners.

Short descriptiontext

1Cell.Ai is a precision oncology company that applies AI-driven single-cell multi-omics (genomic, transcriptomic, proteomic) to cancer diagnostics, serving clinicians, biopharma partners, and cancer patients through CLIA-certified US and NABL-accredited India laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology diagnostics, liquid biopsy testing, single cell analysis, genomic profiling services, cancer diagnostics platform
Industry6 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code4 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Precision Oncology Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Testing Services
TypeOne Time License
Description

Revenue generated from comprehensive genomic profiling tests including OncoIndx (1000+ gene panel), OncoIndx Prime+, OncoRisk (hereditary cancer testing), OncoHRD, OncoMonitor (longitudinal monitoring), and OncoTarget. Tests offered for both tissue (FFPE) and liquid biopsy samples with results delivered via AI-powered iCare platform.

1cell.ai
2Clinical Research Services
TypeProfessional Services
Description

Laboratory services for biopharma clinical trials including biomarker discovery, patient stratification, and companion diagnostic development using the OncoIncytes platform and 1080-gene NGS panel.

1cell.ai
3Biopharma Partnerships
TypeSubscription Recurring
Description

Collaborations with pharmaceutical companies for precision oncology solutions including trial support, biomarker validation, and data services for drug development programs.

1cell.ai
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise diagnostic testing services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for comprehensive genomic profiling tests including OncoIndx, OncoIndx Prime+, OncoRisk, OncoHRD, OncoMonitor, and OncoTarget. Contact sales for pricing details.

1cell.ai
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

1Cell.Ai provides AI-driven single cell multi-omics precision oncology diagnostics through proprietary Cell Biopsy liquid biopsy technology that captures live circulating tumor cells (CTCs) and ctDNA from blood samples. The platform combines an AI-powered informatics suite (iCare/iCore) with a portfolio of NGS-based genomic profiling tests (OncoIndx, OncoRisk, OncoHRD, OncoMonitor, OncoTarget) for cancer detection, therapy selection, hereditary risk assessment, HRD testing, and longitudinal disease monitoring. Services are delivered through CLIA/CAP-certified laboratories in the US and NABL-accredited facilities in India, targeting clinicians, hospitals, biopharma companies, and researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 4× earlier relapse detection through molecular-level signal vs. imaging
+5 more records
Product overview1 text field

1Cell.Ai offers a unified AI-powered single-cell multi-omics precision oncology platform. The portfolio is organized into two main offerings: (1) A global platform comprising OncoIncytes® (live CTC liquid biopsy), 1Cell SOLO® (automated single-cell isolation), and 1Cell iCore™ (AI informatics platform with iDiscover and iCare modules); and (2) An India-specific suite including OncoIndx® (comprehensive 1,000+ gene NGS profiling), OncoIndx® Prime+ (tissue-liquid-normal matched NGS), OncoRisk® (74-gene hereditary cancer panel), OncoHRD® (HRD testing for PARP inhibitor guidance), OncoMonitor® (longitudinal CTC/ctDNA monitoring), OncoTarget® (disease-specific targeted panels), OncoIndx® 360° Endometrium (WHO-aligned endometrial classification), and DrG and OSakhi (clinician and patient companion platforms). All products are supported by AI-powered interpretation through the iCare™ platform and are validated under CAP/CLIA/NABL/ISO quality systems.

Product and service2 records
1OncoIncytes®
CategoryLiquid Biopsy / Diagnostics Platform
Description

Proprietary next-generation liquid biopsy platform that captures and analyzes live circulating tumor cells (CTCs) in real time, combining CTC and ctDNA analysis to provide comprehensive molecular information for personalized therapeutic decisions in oncology.

21Cell SOLO®
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-13
Description

Strategic collaboration to integrate AccuGenomics' Accukit™ CRC/NSCLC Internal Standards with 1Cell.Ai's ultra-sensitive NGS-based OncoIndx panel for per-sample quality control and sensitivity verification. Partnership aims to process tens of thousands of patient samples annually across Asia with plans for US market expansion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-28
Description

CLIA-grade analytical validation study of OncoIncytes 1080-gene NGS panel at the Georgia Cancer Centre's GEM Lab, led by Dr. Ravindra Kolhe. Validation demonstrated high concordance with FDA-approved orthogonal NGS platforms across 15+ tumor types.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Strategic partnership to co-develop and commercialize next-generation single cell multi-omic solutions. Collaboration combines BioSkryb's single cell multi-omics technology with 1Cell.Ai's precision diagnostics platform for enhanced biomarker discovery and clinical applications.

4Academic and Research Institutions
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborative partnerships with leading academic institutions and research hospitals for multi-omic research, clinical validation studies, and biomarker discovery programs. Partner logos displayed on website indicating established relationships.

1cell.ai
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major diagnostics company with Cologuard plus the acquired Genomic Health/Thrive oncology assets (Oncotype DX). Broad incumbent offering oncology diagnostics and screening that competes for hospital and oncologist mindshare.

TypeDirect peer
Description

Cancer genomics company with NeXT Personal MRD test and ImmunoID Next platform for tumor profiling. Direct peer in liquid biopsy MRD and immuno-oncology biomarker discovery, competing for biopharma partnership dollars.

TypeDirect peer
Description

Leading US liquid biopsy company with Guardant360 CDx and Reveal MRD products. Directly competes with 1Cell.Ai's OncoIncytes platform in oncology liquid biopsy and is the most relevant comparator given its commercial scale, Medicare coverage, and biopharma partnerships.

4Tempus
TypeBroad incumbent
Description

AI-powered precision medicine company offering multi-omic profiling, real-world evidence, and biopharma data services. Broad incumbent comparable to 1Cell.Ai's iCORE platform for biomarker-driven clinical trials and AI interpretation.

TypeBroad incumbent
Description

Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx). Comparable as a broad oncology diagnostics incumbent with established payer coverage, biopharma CDx partnerships, and a multi-omic profiling offering that overlaps with 1Cell.Ai's OncoIndx panel.

TypeDirect peer
Description

Molecular diagnostics company with Signatera MRD test and oncology products. Direct peer in tumor-informed liquid biopsy and longitudinal monitoring — overlapping with 1Cell.Ai's OncoMonitor MRD and CTC/ctDNA strategy.

TypeDirect peer
Description

Molecular profiling company offering tissue and liquid biopsy comprehensive genomic profiling plus AI-driven biomarker discovery (MI Profile, MI Cancer Seek). Direct competitor to 1Cell.Ai across the same oncology diagnostics and biopharma services segments.

TypeBroad incumbent
Description

Specialized oncology laboratory services company with comprehensive genomic profiling, MRD, and pharma services. Broad incumbent with overlapping CGP, liquid biopsy, and biopharma clinical trial offerings.

TypeEmerging player
Description

NGS quality control standards provider whose Accukit™ CRC/NSCLC Internal Standards integrate with 1Cell.Ai's OncoIndx panel per October 2025 partnership. Emerging peer/adjoiner enabling ultra-sensitive liquid biopsy QC.

TypeEmerging player
Description

Single-cell multi-omics company and 1Cell.Ai's strategic co-development partner (announced April 2025). Emerging peer with overlapping single-cell technology platform and joint go-to-market alignment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

1Cell.Ai

Precision Oncology Diagnostics1cell.ai

1Cell.Ai is a precision oncology company that applies AI-driven single-cell multi-omics (genomic, transcriptomic, proteomic) to cancer diagnostics, serving clinicians, biopharma partners, and cancer patients through CLIA-certified US and NABL-accredited India laboratories.

What 1Cell.Ai does

1Cell.Ai is a precision oncology company that applies AI to single-cell multi-omic analysis for cancer diagnostics. Originally founded as OneCell Diagnostics in 2019 and rebranded in April 2025, the company operates a CLIA/CAP certified laboratory in Foster City, California and an NABL accredited laboratory in Pune, India, with a regional headquarters in Mumbai. Its core technology stack combines a proprietary live circulating tumor cell (CTC) capture platform (Cell Biopsy®, OncoIncytes®) achieving over 82% single-cell capture efficiency, an AI-driven automated single-cell isolation system (1Cell SOLO®), and an AI-powered informatics platform (1Cell iCore™ with iDiscover and iCare modules) that integrates genomic, transcriptomic, proteomic, imaging, and clinical data with real-world evidence. AI capabilities span deep-learning digital pathology (OncoPredikt, TRINITYAI), ctDNA methylation-driven MRD detection (MIRAGE), predictive therapy response modeling, and variant interpretation ML.

The company's product portfolio is organized into a global platform (OncoIncytes, 1Cell SOLO, 1Cell iCore) and an India-focused diagnostic suite (OncoIndx comprehensive 1,000+ gene NGS profiling, OncoIndx Prime+ matched tissue-liquid-normal NGS, OncoRisk hereditary 74-gene panel, OncoHRD for PARP inhibitor guidance, OncoMonitor longitudinal CTC/ctDNA monitoring, OncoTarget disease-specific panels, OncoIndx 360° Endometrium, and DrG/OSakhi clinician and patient companion platforms). All tests are supported by AI-powered interpretation through the iCare™ platform and validated under CAP/CLIA/NABL/ISO quality systems.

Revenue is generated through three streams: one-time diagnostic testing services sold quote-based to hospitals and oncologists, clinical research and biomarker discovery services for biopharma partners, and recurring biopharma partnerships for trial support and companion diagnostic development. GTM is enterprise field sales augmented by active presence at major oncology conferences (AACR, SABCS, ESMO, ISLB, World ADC). Strategic alliances include BioSkryb Genomics (single cell multi-omics co-development, April 2025), AccuGenomics (Accukit integration for Asia scale-up, October 2025), and Georgia Cancer Centre (CLIA-grade validation, May 2025). Customers served include 100+ hospitals, 1,000+ clinicians, and 50,000+ patients cumulatively, with primary segments being clinicians/oncologists and pharma/biopharma partners.

1Cell.Ai firmographics

Firmographics
Name
1Cell.Ai
Legal name
1Cell.Ai Inc.
Website
https://1cell.ai
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
1Cell.Ai is a precision oncology company that applies AI-driven single-cell multi-omics (genomic, transcriptomic, proteomic) to cancer diagnostics, serving clinicians, biopharma partners, and cancer patients through CLIA-certified US and NABL-accredited India laboratories.
Ownership category
akta.pro rank

1Cell.Ai industry classification

Industry
Product category
Precision Oncology Diagnostics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Precision oncology diagnostics
  • Liquid biopsy testing
  • Single cell analysis
  • Genomic profiling services
  • Cancer diagnostics platform

Where 1Cell.Ai is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices5 records

Markets served

1Cell.Ai business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: Revenue generated from comprehensive genomic profiling tests including OncoIndx (1000+ gene panel), OncoIndx Prime+, OncoRisk (hereditary cancer testing), OncoHRD, OncoMonitor (longitudinal monitoring), and OncoTarget. Tests offered for both tissue (FFPE) and liquid biopsy samples with results delivered via AI-powered iCare platform.
  2. Clinical Research Services: Laboratory services for biopharma clinical trials including biomarker discovery, patient stratification, and companion diagnostic development using the OncoIncytes platform and 1080-gene NGS panel.
  3. Biopharma Partnerships: Collaborations with pharmaceutical companies for precision oncology solutions including trial support, biomarker validation, and data services for drug development programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise diagnostic testing services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

1Cell.Ai product offering

Product offering

Core offering

1Cell.Ai provides AI-driven single cell multi-omics precision oncology diagnostics through proprietary Cell Biopsy liquid biopsy technology that captures live circulating tumor cells (CTCs) and ctDNA from blood samples. The platform combines an AI-powered informatics suite (iCare/iCore) with a portfolio of NGS-based genomic profiling tests (OncoIndx, OncoRisk, OncoHRD, OncoMonitor, OncoTarget) for cancer detection, therapy selection, hereditary risk assessment, HRD testing, and longitudinal disease monitoring. Services are delivered through CLIA/CAP-certified laboratories in the US and NABL-accredited facilities in India, targeting clinicians, hospitals, biopharma companies, and researchers.

Product overview

1Cell.Ai offers a unified AI-powered single-cell multi-omics precision oncology platform. The portfolio is organized into two main offerings: (1) A global platform comprising OncoIncytes® (live CTC liquid biopsy), 1Cell SOLO® (automated single-cell isolation), and 1Cell iCore™ (AI informatics platform with iDiscover and iCare modules); and (2) An India-specific suite including OncoIndx® (comprehensive 1,000+ gene NGS profiling), OncoIndx® Prime+ (tissue-liquid-normal matched NGS), OncoRisk® (74-gene hereditary cancer panel), OncoHRD® (HRD testing for PARP inhibitor guidance), OncoMonitor® (longitudinal CTC/ctDNA monitoring), OncoTarget® (disease-specific targeted panels), OncoIndx® 360° Endometrium (WHO-aligned endometrial classification), and DrG and OSakhi (clinician and patient companion platforms). All products are supported by AI-powered interpretation through the iCare™ platform and are validated under CAP/CLIA/NABL/ISO quality systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • OncoIncytes® Proprietary next-generation liquid biopsy platform that captures and analyzes live circulating tumor cells (CTCs) in real time, combining CTC and ctDNA analysis to provide comprehensive molecular information for personalized therapeutic decisions in oncology.
  • 1Cell SOLO®

Quantifiable outcome

  • 4× earlier relapse detection through molecular-level signal vs. imaging
  • +5 more outcomes

Companies that use 1Cell.Ai

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

1Cell.Ai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature6 records

1Cell.Ai partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • AccuGenomicscoreTechnology or Integration · 13 October 2025Strategic collaboration to integrate AccuGenomics' Accukit™ CRC/NSCLC Internal Standards with 1Cell.Ai's ultra-sensitive NGS-based OncoIndx panel for per-sample quality control and sensitivity verification. Partnership aims to process tens of thousands of patient samples annually across Asia with plans for US market expansion.
  • Georgia Cancer Center / Dr. Ravindra KolhecoreStrategic or Co-development Partner · 28 May 2025CLIA-grade analytical validation study of OncoIncytes 1080-gene NGS panel at the Georgia Cancer Centre's GEM Lab, led by Dr. Ravindra Kolhe. Validation demonstrated high concordance with FDA-approved orthogonal NGS platforms across 15+ tumor types.
  • BioSkryb GenomicscoreStrategic or Co-development Partner · 24 April 2025Strategic partnership to co-develop and commercialize next-generation single cell multi-omic solutions. Collaboration combines BioSkryb's single cell multi-omics technology with 1Cell.Ai's precision diagnostics platform for enhanced biomarker discovery and clinical applications.
  • Academic and Research InstitutionsmajorStrategic or Co-development PartnerCollaborative partnerships with leading academic institutions and research hospitals for multi-omic research, clinical validation studies, and biomarker discovery programs. Partner logos displayed on website indicating established relationships.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

1Cell.Ai competitors and assessment

Company assessment

Broad incumbents

  • Exact Sciences: Major diagnostics company with Cologuard plus the acquired Genomic Health/Thrive oncology assets (Oncotype DX). Broad incumbent offering oncology diagnostics and screening that competes for hospital and oncologist mindshare.
  • Tempus: AI-powered precision medicine company offering multi-omic profiling, real-world evidence, and biopharma data services. Broad incumbent comparable to 1Cell.Ai's iCORE platform for biomarker-driven clinical trials and AI interpretation.
  • Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx). Comparable as a broad oncology diagnostics incumbent with established payer coverage, biopharma CDx partnerships, and a multi-omic profiling offering that overlaps with 1Cell.Ai's OncoIndx panel.
  • NeoGenomics: Specialized oncology laboratory services company with comprehensive genomic profiling, MRD, and pharma services. Broad incumbent with overlapping CGP, liquid biopsy, and biopharma clinical trial offerings.

Direct peers

  • Personalis: Cancer genomics company with NeXT Personal MRD test and ImmunoID Next platform for tumor profiling. Direct peer in liquid biopsy MRD and immuno-oncology biomarker discovery, competing for biopharma partnership dollars.
  • Guardant Health: Leading US liquid biopsy company with Guardant360 CDx and Reveal MRD products. Directly competes with 1Cell.Ai's OncoIncytes platform in oncology liquid biopsy and is the most relevant comparator given its commercial scale, Medicare coverage, and biopharma partnerships.
  • Natera: Molecular diagnostics company with Signatera MRD test and oncology products. Direct peer in tumor-informed liquid biopsy and longitudinal monitoring — overlapping with 1Cell.Ai's OncoMonitor MRD and CTC/ctDNA strategy.
  • Caris Life Sciences: Molecular profiling company offering tissue and liquid biopsy comprehensive genomic profiling plus AI-driven biomarker discovery (MI Profile, MI Cancer Seek). Direct competitor to 1Cell.Ai across the same oncology diagnostics and biopharma services segments.

Emerging players

  • AccuGenomics: NGS quality control standards provider whose Accukit™ CRC/NSCLC Internal Standards integrate with 1Cell.Ai's OncoIndx panel per October 2025 partnership. Emerging peer/adjoiner enabling ultra-sensitive liquid biopsy QC.
  • BioSkryb Genomics: Single-cell multi-omics company and 1Cell.Ai's strategic co-development partner (announced April 2025). Emerging peer with overlapping single-cell technology platform and joint go-to-market alignment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

1Cell.Ai social profiles

Digital presence

1Cell.Ai compliance and trust

Trust signal

Compliance5 records

1Cell.Ai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

1Cell.Ai leadership team

Management profile

Number of profiles

Profiles9 records

1Cell.Ai funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

1Cell.Ai M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 1Cell.Ai

What does 1Cell.Ai do?

1Cell.Ai provides AI-driven single cell multi-omics precision oncology diagnostics through proprietary Cell Biopsy liquid biopsy technology that captures live circulating tumor cells (CTCs) and ctDNA from blood samples. The platform combines an AI-powered informatics suite (iCare/iCore) with a portfolio of NGS-based genomic profiling tests (OncoIndx, OncoRisk, OncoHRD, OncoMonitor, OncoTarget) for cancer detection, therapy selection, hereditary risk assessment, HRD testing, and longitudinal disease monitoring. Services are delivered through CLIA/CAP-certified laboratories in the US and NABL-accredited facilities in India, targeting clinicians, hospitals, biopharma companies, and researchers.

Is 1Cell.Ai a public or private company?

1Cell.Ai is a private company. It is classified as unknown and is currently operating.

When was 1Cell.Ai founded?

1Cell.Ai was founded in 2019. It employs 101 to 250 people.

Where is 1Cell.Ai based?

1Cell.Ai is headquartered in Mumbai, India, in the Asia region.

How does 1Cell.Ai make money?

Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are clinical Research Services and biopharma Partnerships.

Who are 1Cell.Ai's main competitors?

Broad incumbents on record are Exact Sciences, Tempus, Foundation Medicine and NeoGenomics. Direct peers are Personalis, Guardant Health, Natera and Caris Life Sciences. Emerging players are AccuGenomics and BioSkryb Genomics.

Does 1Cell.Ai have an API?

No public API is recorded for 1Cell.Ai.

What industry is 1Cell.Ai in?

1Cell.Ai's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 6215 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals